Yes, several DAAs have been approved for use in children by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For example, Sofosbuvir and Ledipasvir are approved for use in children aged 3 years and older for the treatment of Hepatitis C. The approval of these medications for pediatric use is based on clinical trials demonstrating their safety and efficacy in children.
